Catalyst
Slingshot members are tracking this event:
Novartis (NVS) to submit CL-019 for Diffuse large B-cell lymphoma (DLBCL) in the U.S. in Q4 of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 01, 2018
Occurred Source:
https://www.novartis.com/news/media-releases/kymriahr-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Diffuse Large B-cell Lymphoma (dlbcl), Ctl019
